Evidence Hub

Non-beta-oxidizable omega-[18F]fluoro long chain fatty acid analogs show cytochrome P-450-mediated defluorination: implications for the design of PET tracers of myocardial fatty acid utilization

DeGrado TR, Moka DC

International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology, 1992

Abstract

The nature of the in vivo defluorination of non-beta-oxidazable no-carrier-added omega-[18F]fluoro long chain fatty acid (LCFA) analogs was studied with the aim of developing PET tracers of LCFA utilization. Extensive defluorination of 15-[18F]fluoro-3-thia-pentadecanoic acid (FTPA) in mouse was evidenced by radioactivity uptake by bone. [18F]Fluoride in the blood was verified analytically. Incubations of FTPA in rat-liver homogenates and subcellular fractions thereof showed a strong defluorination process in microsomes which was O2- and NADPH-dependent. In contrast, defluorination of FTPA was relatively slow in Langendorff perfused rat heart. High bone uptake in mouse was also observed with 14-[18F]fluoro-13,13-dimethyl-3-thia-tetradecanoic acid, where gem-dimethyl substitution precludes direct elimination of H18F. These data indicate that the defluorination of non-beta-oxidizable omega-[18F]fluoro LCFA analogs is primarily governed by cytochrome P-450-mediated omega-oxidation. Therefore, labeling at the (omega-3) carbon was proposed to provide a more stabile 18F-label. Defluorination of the (omega-3)-labeled 13 (R,S)-[18F]fluoro-3-thia-hexadecanoic acid was lower than that of FTPA in mouse and was independent of O2 and NADPH in vitro. Thus, (omega-3) labeling with 18F is preferable to omega labeling of non-beta-oxidizable LCFA analogs.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free